UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

March 25, 2013

 

 

Omni Bio Pharmaceutical, Inc.

(Exact name of registrant as specified in its charter)

 

Colorado

000-52530

 20-8097969

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

 

 

5350 South Roslyn, Suite 430, Greenwood Village, CO

80111

(Address of principal executive offices)

(Zip Code)

 

(303) 867-3415

(Registrant’s telephone number, including area code)

 
 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 

Item 8.01     Other Events.

 

On March 25, 2013, the Board of Directors of Omni Bio Pharmaceutical, Inc. (the “Company”) approved the amendment of certain warrants to purchase an aggregate of 5,610,000 shares of common stock of the Company (the “Warrants”) to extend the expiration date of the Warrants from March 31, 2014 to March 31, 2017. All other terms of the Warrants remain unchanged. Substantially all of the Warrants are held by greater than 10% shareholders of the Company.

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Omni Bio Pharmaceutical, Inc.

 

Date: March 26, 2013

       
By: /s/ Robert C. Ogden    
   

Robert C. Ogden

 
   

Chief Financial Officer